Ardent Health (ARDT)
Market Price (12/26/2025): $8.965 | Market Cap: $1.3 BilSector: Health Care | Industry: Health Care Facilities
Ardent Health (ARDT)
Market Price (12/26/2025): $8.965Market Cap: $1.3 BilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 16%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 12%, FCF Yield is 12% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 132% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -35% | Key risksARDT key risks include [1] significant adverse accounting adjustments to revenue and liability reserves, Show more. |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Oncology Treatments, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 16%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 12%, FCF Yield is 12% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -35% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Oncology Treatments, Show more. |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 132% |
| Key risksARDT key risks include [1] significant adverse accounting adjustments to revenue and liability reserves, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Here are five key points explaining the approximate -29.3% movement in Ardent Health (ARDT) stock from August 31, 2025, to December 26, 2025: 1. Lowered FY2025 Earnings Guidance: Ardent Health issued its Q3 earnings results on November 12, 2025, reporting earnings per share (EPS) of $0.52 against an expected $0.42, and revenue of $1.58 billion versus an expected $1.55 billion. However, the company's full-year 2025 EPS guidance of $0.85–$1.03 fell below the consensus forecast of approximately $1.23, which likely contributed to investor concern.2. Analyst Downgrades and Trimmed Price Targets: Following financial announcements, several brokerage firms, including RBC, Guggenheim, JPMorgan, and KeyCorp, reportedly trimmed their price targets or ratings for ARDT stock. As of December 25, 2025, Ardent Health received a consensus recommendation of "Hold" from twelve analysts, with an average 12-month target price of $14.67, indicating a cautious outlook from the financial community.
Show more
Stock Movement Drivers
Fundamental Drivers
The -32.0% change in ARDT stock from 9/25/2025 to 12/25/2025 was primarily driven by a -21.2% change in the company's Net Income Margin (%).| 9252025 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 13.19 | 8.97 | -31.99% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 6198.62 | 6325.55 | 2.05% |
| Net Income Margin (%) | 4.11% | 3.24% | -21.15% |
| P/E Multiple | 7.26 | 6.18 | -14.97% |
| Shares Outstanding (Mil) | 140.37 | 141.23 | -0.61% |
| Cumulative Contribution | -32.00% |
Market Drivers
9/25/2025 to 12/25/2025| Return | Correlation | |
|---|---|---|
| ARDT | -32.0% | |
| Market (SPY) | 4.9% | 31.0% |
| Sector (XLV) | 16.2% | 16.2% |
Fundamental Drivers
The -32.6% change in ARDT stock from 6/26/2025 to 12/25/2025 was primarily driven by a -25.5% change in the company's P/E Multiple.| 6262025 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 13.31 | 8.97 | -32.61% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 6024.26 | 6325.55 | 5.00% |
| Net Income Margin (%) | 3.73% | 3.24% | -13.08% |
| P/E Multiple | 8.30 | 6.18 | -25.54% |
| Shares Outstanding (Mil) | 140.06 | 141.23 | -0.83% |
| Cumulative Contribution | -32.61% |
Market Drivers
6/26/2025 to 12/25/2025| Return | Correlation | |
|---|---|---|
| ARDT | -32.6% | |
| Market (SPY) | 13.1% | 28.2% |
| Sector (XLV) | 16.6% | 15.5% |
Fundamental Drivers
The -44.2% change in ARDT stock from 12/25/2024 to 12/25/2025 was primarily driven by a -82.1% change in the company's P/E Multiple.| 12252024 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 16.07 | 8.97 | -44.18% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 4951.74 | 6325.55 | 27.74% |
| Net Income Margin (%) | 1.32% | 3.24% | 144.66% |
| P/E Multiple | 34.53 | 6.18 | -82.11% |
| Shares Outstanding (Mil) | 140.96 | 141.23 | -0.19% |
| Cumulative Contribution | -44.18% |
Market Drivers
12/25/2024 to 12/25/2025| Return | Correlation | |
|---|---|---|
| ARDT | -44.2% | |
| Market (SPY) | 15.8% | 25.9% |
| Sector (XLV) | 13.3% | 30.8% |
Fundamental Drivers
nullnull
Market Drivers
12/26/2023 to 12/25/2025| Return | Correlation | |
|---|---|---|
| ARDT | ||
| Market (SPY) | 48.3% | 24.5% |
| Sector (XLV) | 18.5% | 28.1% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ARDT Return | � | � | � | � | � | -48% | -48% |
| Peers Return | 51% | 64% | -30% | 13% | 12% | 25% | 172% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 115% |
Monthly Win Rates [3] | |||||||
| ARDT Win Rate | � | � | � | � | 40% | 42% | |
| Peers Win Rate | 55% | 65% | 45% | 55% | 55% | 57% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| ARDT Max Drawdown | � | � | � | � | � | -52% | |
| Peers Max Drawdown | -53% | -6% | -53% | -19% | -11% | -15% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HCA, THC, UHS, CYH, SGRY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/24/2025 (YTD)
How Low Can It Go
ARDT has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-2 brief analogies to describe Ardent Health:
- Like Marriott, but for hospitals.
- A smaller, regional version of HCA Healthcare.
AI Analysis | Feedback
- Acute Care Hospital Services: Providing a full spectrum of inpatient and outpatient medical and surgical care through their network of hospitals.
- Physician Services: Offering primary and specialty care, including consultations, diagnostics, and treatments, through employed and affiliated physician practices.
- Emergency Services: Delivering immediate medical attention for urgent and critical conditions via hospital emergency departments.
AI Analysis | Feedback
Ardent Health (symbol: ARDT) primarily sells its healthcare services directly to individuals. As a hospital operator and healthcare provider, its major customers are the patients who receive medical care through its network of hospitals, physician clinics, and urgent care centers. These customers can be broadly categorized as:
-
Patients Requiring Acute and Inpatient Hospital Care: These include individuals admitted to Ardent's hospitals for serious illnesses, injuries, complex surgeries, emergency medical conditions, or other treatments that necessitate an overnight stay and intensive medical attention.
-
Patients Utilizing Outpatient and Ambulatory Services: This category encompasses individuals who visit Ardent's facilities for services that do not require an overnight hospital stay. This includes appointments at physician clinics, urgent care visits, diagnostic imaging (e.g., X-rays, MRIs), laboratory tests, physical therapy, and various other specialized outpatient procedures and consultations.
-
Patients Seeking Specialized Programs and Chronic Disease Management: This group includes individuals participating in specific health programs such as maternity care, behavioral health services, rehabilitation, or those receiving ongoing, coordinated care for chronic medical conditions through Ardent's integrated health systems.
AI Analysis | Feedback
nullAI Analysis | Feedback
Marty Bonick, President & Chief Executive Officer
Mr. Bonick has served as President and CEO of Ardent Health Services since 2020. He has nearly 25 years of healthcare leadership experience across for-profit, non-profit, public, and privately held companies. Prior to Ardent, he was CEO of PhyMed Healthcare Group, a national provider of anesthesia and pain management services, where he drove significant growth organically and through acquisitions. He also served as a Division President at Community Health Systems (CHS), overseeing a $4.5 billion portfolio of 36 hospitals, and was CEO of Jewish Hospital and Senior Vice President of Operations for Jewish Hospital & St. Mary's Healthcare. Mr. Bonick began his career at Hillcrest HealthCare System, which Ardent Health Services acquired in 2004 during his tenure. Ardent Health Services is one of the largest private health systems in the U.S. and was backed by Equity Group Investments and Ventas Inc. at the time of his appointment, indicating a pattern of managing companies with private equity involvement.
Alfred Lumsdaine, Chief Financial Officer
Mr. Lumsdaine joined Ardent Health Services as CFO in 2021. With over 30 years of healthcare finance experience, he provides financial oversight and develops long-range financial plans. Before Ardent, he was Executive Vice President and CFO for Quorum Health from 2018 to 2021, where he oversaw financial operations for 22 acute care hospitals and led a major financial restructuring that significantly reduced company debt. Prior to Quorum Health, he was President of Population Health for Sharecare and spent five years as CFO for Tivity Health (formerly Healthways) before its acquisition by Sharecare, demonstrating experience with companies involved in acquisitions. He began his career at Ernst & Young, focusing on healthcare in the external audit practice. He is a Certified Public Accountant (CPA).
FJ Campbell, MD, Chief Medical Officer
Dr. Campbell has been with Ardent since 2017. Prior to joining Ardent, he served as the Vice President of Chief Medical Services at Community Health Systems (CHS) from 2014 to 2017. He also previously held the role of Chief Medical Officer for CareSpot Express Healthcare.
Steve Petrovich, Chief Legal Officer
Mr. Petrovich has been with Ardent since its formation in 2001 and previously served as general counsel for its predecessor company, Behavioral Health Corporation. Before that, he was chief litigation counsel for Charter Behavioral Health Systems and maintained a private legal practice specializing in general litigation, anti-trust, employment, and healthcare regulatory matters.
Carolyn Schneider, Chief Human Resources Officer
Ms. Schneider joined Ardent in 2021. She previously served as the Chief Human Resources Officer for Corizon Health, a prison healthcare contractor. Ms. Schneider has extensive experience working in the private equity-backed and investor-owned health system sectors.
AI Analysis | Feedback
Ardent Health (ARDT) faces several key risks to its business operations:-
Accounting Adjustments and Legal Scrutiny: Ardent Health recently disclosed significant adverse accounting adjustments in Q3 2025, including a $43 million reduction in revenue and a $54 million increase in professional liability reserves related to prior period claims and ongoing litigation. These revelations led to a substantial decline in the company's stock price and prompted investigations by shareholder rights law firms into potential securities law violations and material weaknesses in internal controls regarding revenue recognition and liability reserves. This situation has also brought to light concerns about payer denials and reimbursement pressure.
-
Legislative and Reimbursement Risks: The company is exposed to significant legislative risks, particularly concerning potential cuts to government healthcare programs like Medicaid and Medicare. A substantial portion of Ardent Health's net patient service revenue is derived from these programs (40.5% from Medicare and 10.2% from Medicaid in Q1 2025). Legislative changes, such as proposed spending bills impacting Medicaid funding, introduce considerable uncertainty and can negatively affect the company's financial performance.
-
Staffing and Labor Shortages: Ardent Health faces ongoing challenges in recruiting and retaining qualified healthcare professionals, including nurses, physicians, and management personnel. Increased competition for skilled labor and a general shortage of experienced nurses could adversely impact the company's ability to operate efficiently and deliver services.
AI Analysis | Feedback
Clear Emerging Threats for Ardent Health (ARDT):
- Accelerated Shift to Lower-Cost, Outpatient Care Settings: Advances in medical technology, less invasive procedures, and persistent payer pressures for cost containment are driving a significant and growing migration of procedures, diagnostics, and even certain types of surgeries from traditional, expensive inpatient hospital settings to ambulatory surgery centers (ASCs), outpatient clinics, and physician offices. This trend directly threatens the utilization and revenue streams of Ardent's core business of acute care hospitals, as patients and payers increasingly favor the convenience and lower cost of these alternative sites of care where clinically appropriate.
- Expansion of Integrated Retail and Payer Health Ecosystems: Major retail corporations (e.g., CVS Health, Walgreens, Walmart) and large health insurers (e.g., UnitedHealth Group's Optum) are aggressively building and acquiring extensive direct-to-consumer health services networks. These ecosystems encompass primary care clinics, urgent care centers, specialty practices, and home health services, aiming to manage patient care comprehensively within their own integrated systems. This development introduces powerful new competitors that can divert patient volume, referrals, and market share away from independent hospital systems like Ardent, particularly for less acute conditions, primary care, and ongoing chronic disease management.
AI Analysis | Feedback
nullAI Analysis | Feedback
Ardent Health (symbol: ARDT) is expected to drive future revenue growth over the next 2-3 years through several key strategies:
-
Increased Patient Volumes: Ardent Health anticipates continued growth in patient volumes, specifically through adjusted admissions and surgeries. The company reported a 3.8% year-over-year increase in adjusted admissions in Q3 2024 and a significant 9.0% increase in Q4 2024. In Q2 2025, admissions grew 6.6% year-over-year, driven by a 9.2% increase in inpatient surgeries. For the full year 2025, Ardent Health projects adjusted admissions growth between 2.0% and 3.0%. This growth is supported by Ardent's strong positions in growing mid-sized urban markets and an aging patient population, which is expected to continue driving demand for healthcare services.
-
Higher Net Patient Service Revenue per Adjusted Admission: The company expects to increase revenue through improved pricing and reimbursement rates. Ardent Health's full-year 2024 guidance projected net patient service revenue per adjusted admission growth of 2.3% to 4.4%. In Q2 2025, the company saw a 10.2% year-over-year growth in net patient service revenue per adjusted admission. This trend is expected to continue, with full-year 2025 guidance forecasting an increase between 2.1% and 4.4% in net patient service revenue per adjusted admission. Strategic initiatives also include optimizing payer contracts to enhance margins.
-
Strategic Expansion of Outpatient Services and Acute Care Facilities: Ardent Health is actively pursuing an ambulatory growth strategy and opportunistic mergers and acquisitions (M&A) to expand its footprint and service offerings. The company plans to open additional urgent care and imaging centers, complementing recent acquisitions. This expansion beyond traditional hospital settings, particularly in outpatient services, is aimed at generating new revenue streams and positioning the company for value-based care. Ardent's strategic priorities emphasize driving market share within its existing footprint and expanding its outpatient and acute care hospital presence.
-
State Directed Payment Programs and Operational Efficiencies: The approval and renewal of state-directed payment programs, such as the New Mexico Directed Payment Program (DPP), are significant contributors to revenue. The New Mexico DPP was retroactively approved in November 2024 for the second half of 2024, providing a substantial benefit to total revenue. Its renewal for the full calendar year 2025 is a positive development that will continue to support revenue. Additionally, Ardent Health is focused on operational excellence and margin improvement initiatives, including supply chain optimization and cost management, which are expected to lead to sustainable profitable growth and free up resources for further investment.
AI Analysis | Feedback
Share Issuance
- Ardent Health went public in July 2024, raising $192 million in its initial public offering (IPO) by selling 12 million shares at $16 each.
- After accounting for options granted to underwriters, the proceeds generated $209 million.
- The proceeds from the IPO are expected to be allocated towards debt repayment and future acquisitions, with a particular focus on expanding ambulatory services and outpatient sites of care.
Inbound Investments
- Equity Group Investments (EGI) remains a significant shareholder following Ardent Health's IPO in July 2024, having acquired a majority stake in the company in 2015.
- In February 2022, Ardent completed a sale-leaseback transaction with Ventas, a related party REIT shareholder, selling 18 medical office buildings for $204 million.
- Ardent Health has leveraged capital from private investors, public markets, a UAE minority investment, and a real estate investment trust.
Outbound Investments
- In January 2025, Ardent Health acquired 18 urgent care clinics across New Mexico and Oklahoma from NextCare Urgent Care.
- The company acquired nine additional urgent care centers in its East Texas and Topeka, Kansas, markets in 2024.
- Ardent's strategy includes expanding its footprint in ambulatory care through acquisitions and growing its portfolio of joint ventures.
Capital Expenditures
- Capital expenditures are expected to range from $215 million to $235 million for the full year 2025.
- A primary focus for capital expenditures is investing in ambulatory assets, including both mergers and acquisitions (M&A) and de novo developments, to increase outpatient access points.
- Capital investment also targets new service lines, equipment, and technology to expand offerings.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ARDT. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.1% | 21.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.7% | -6.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 16.7% | 16.7% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.8% | 11.8% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Ardent Health
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 106.70 |
| Mkt Cap | 8.1 |
| Rev LTM | 14,818 |
| Op Inc LTM | 1,516 |
| FCF LTM | 572 |
| FCF 3Y Avg | 470 |
| CFO LTM | 1,221 |
| CFO 3Y Avg | 983 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.3% |
| Rev Chg 3Y Avg | 6.6% |
| Rev Chg Q | 6.5% |
| QoQ Delta Rev Chg LTM | 1.6% |
| Op Mgn LTM | 13.3% |
| Op Mgn 3Y Avg | 11.8% |
| QoQ Delta Op Mgn LTM | 0.4% |
| CFO/Rev LTM | 10.0% |
| CFO/Rev 3Y Avg | 9.5% |
| FCF/Rev LTM | 5.7% |
| FCF/Rev 3Y Avg | 5.3% |
Price Behavior
| Market Price | $8.97 | |
| Market Cap ($ Bil) | 1.3 | |
| First Trading Date | 07/18/2024 | |
| Distance from 52W High | -47.5% | |
| 50 Days | 200 Days | |
| DMA Price | $11.26 | $15.04 |
| DMA Trend | down | down |
| Distance from DMA | -20.4% | -40.4% |
| 3M | 1YR | |
| Volatility | 75.6% | 56.8% |
| Downside Capture | 280.18 | 91.29 |
| Upside Capture | 38.20 | 19.74 |
| Correlation (SPY) | 30.7% | 25.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.55 | 2.22 | 2.03 | 1.73 | 0.78 | 0.22 |
| Up Beta | -1.49 | -0.76 | -0.31 | 1.40 | 0.79 | -0.01 |
| Down Beta | 10.52 | 4.80 | 4.72 | 4.02 | 0.96 | -0.15 |
| Up Capture | 32% | 56% | 45% | 10% | 22% | 5% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 7 | 20 | 32 | 63 | 120 | 168 |
| Down Capture | 561% | 305% | 244% | 175% | 101% | 75% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 11 | 20 | 29 | 59 | 121 | 167 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
nullBased On 5-Year Data
nullBased On 10-Year Data
nullReturns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2025 | -33.8% | -38.6% | -36.7% |
| 8/5/2025 | 6.1% | 17.1% | 20.8% |
| 2/26/2025 | 8.2% | 9.4% | -6.1% |
| 11/6/2024 | 7.8% | 4.5% | 2.3% |
| 8/14/2024 | 6.1% | 5.7% | 13.4% |
| SUMMARY STATS | |||
| # Positive | 4 | 4 | 3 |
| # Negative | 1 | 1 | 2 |
| Median Positive | 7.0% | 7.5% | 13.4% |
| Median Negative | -33.8% | -38.6% | -21.4% |
| Max Positive | 8.2% | 17.1% | 20.8% |
| Max Negative | -33.8% | -38.6% | -36.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11142025 | 10-Q 9/30/2025 |
| 6302025 | 8062025 | 10-Q 6/30/2025 |
| 3312025 | 5072025 | 10-Q 3/31/2025 |
| 12312024 | 2272025 | 10-K 12/31/2024 |
| 9302024 | 11072024 | 10-Q 9/30/2024 |
| 6302024 | 8142024 | 10-Q 6/30/2024 |
| 12312023 | 7182024 | 424B4 12/31/2023 |
| 12312018 | 3062019 | S-1/A 12/31/2018 |
| 12312017 | 12212018 | S-1/A 12/31/2017 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.